MyScreen Trial FAQ
Frequently Asked Questions
The MyScreen Trial is the first Australian study to explore risk-adjusted BreastScreen screening pathways. This page answers common questions about the trial, participation, and what to expect.
If you can't find the information you're looking for, please contact us and our team will be happy to help.
Who is being invited?
This is a pilot-level trial that will offer additional imaging to approximately 750 participants from the BreastScreen Victoria program. Participation will be by invitation only.
When is the trial happening?
The trial will start recruitment once ethics and other approvals are in place, and recruitment will continue for about 18 months.
Why is the trial being done?
The current breast screening program (BreastScreen) offers mammograms based on age and sex. The program invites women, trans and gender diverse people to screening when they turn 50. People aged 40-49 can also attend screening but they are not routinely invited. The aim of breast screening is to find breast cancers at an early stage in their development. This is important because early detection saves lives. Early detection also leads to less intense cancer treatment and better quality of life after treatment.
Risk-adjusted screening would involve offering more sensitive screening tests to people who are likely to benefit from those tests. This includes people with higher breast density and with other risk factors for breast cancer. MRI or contrast-enhanced mammography (CEM) can be more sensitive than mammography, especially for people with high breast density.
What outcomes will the trial be looking at?
The trial will focus on how acceptable additional screening tests are and how easy they are to provide. It will also look closely at any clinical outcomes, plus the costs of providing the additional screens. We’ll compare outcomes in the group of trial participants with usual outcomes from the BreastScreen Victoria program, for a comparable group of people. We’ll use the findings to estimate the clinical and cost effectiveness of larger-scale implementation of risk-adjusted screening.
Who is funding the MyScreen trial?
The MyScreen Trial is funded by a National Breast Cancer Foundation Research Project Grant (2025RPG0065) with additional support from the Royal Melbourne Hospital Foundation, Breast Cancer Trials, and BreastScreen Victoria.
How does MyScreen address the ROSA Project and the 2026 BreastScreen review?
As outlined in the 2023 ROSA Project recommendations, a more risk-based approach to breast screening may improve the effectiveness of breast screening, and while several trials are underway internationally (e.g. MyPeBS and the WISDOM trial), Australian trials are needed to understand how this could best be implemented in the Australian health system and populations.
The subsequent review of the BreastScreen Australia program considered the ROSA recommendations and in 2026 set forward a goal that by 2036, BreastScreen Australia will lead the way in equitable, high-quality breast cancer screening – using technology and personalised risk-stratified approaches to save more lives through early detection. Recommended actions include piloting new screening pathways for different risk categories.
The MyScreen trial directly addresses the recommendations of the ROSA project and the BreastScreen review, generating important evidence to inform how to best implement risk-stratified breast screening at a population level.